ReviewFrontiers in immunology2026
Artificial intelligence in ovarian cancer: advancing in precision diagnosis and clinical management.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian cancer remains one of the deadliest gynecologic malignancies. Poor outcomes largely reflect late diagnosis, marked inter- and intratumoral heterogeneity, and variable treatment response. Methods: This review summarizes recent advances in artificial intelligence (AI) for ovarian cancer research and clinical care, focusing on imagine-based radiology, digital pathology; longitudinal clinical data/Electronic Health Record (EHR), and spatial-temporal multi-omics. Results: AI approaches have been applied to tumor detection and classification, prognostic risk stratification, and treatment response prediction. Multimodal models that integrate imaging, molecular profiling, and clinical data enable more refined characterization of tumor heterogeneity and the tumor microenvironment, supporting improved diagnosis, risk assessment, and individualized management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.